Current Vascular Pharmacology
Title: Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Volume: 6 Issue: 2
Author(s): Asterios Karagiannis, Dimitri P. Mikhailidis, Konstantinos Tziomalos, Anna I. Kakafika and Vasilios G. Athyros
Affiliation:
Export Options
About this article
Cite this article as:
Karagiannis Asterios, Mikhailidis P. Dimitri, Tziomalos Konstantinos, Kakafika I. Anna and Athyros G. Vasilios, Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ], Current Vascular Pharmacology 2008; 6 (2) . https://dx.doi.org/10.2174/157016108783955329
DOI https://dx.doi.org/10.2174/157016108783955329 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Cardiovascular Drug Discovery “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications
Current Cardiology Reviews Preface (Hot Topic: Endocrine , Metabolic and Immunological Agents Executive Editors : Allan S . Wagman / Wayne L . Cody)
Current Pharmaceutical Design The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness
Current Pharmaceutical Design Antibiotic Susceptibility Evaluation of Bacterial Agents Causing Infection in Children with Acute Tonsillopharyngitis
Infectious Disorders - Drug Targets Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Current Cardiology Reviews Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Redox Chemistry of Green Tea Polyphenols: Therapeutic Benefits in Neurodegenerative Diseases
Mini-Reviews in Medicinal Chemistry The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Current Pharmaceutical Biotechnology PDE-5 Inhibitors: Clinical Points
Current Drug Targets Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets